Confronting the stigma of opioid use disorder—and its treatment Y Olsen, JM Sharfstein Jama 311 (14), 1393-1394, 2014 | 428 | 2014 |
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009 RP Schwartz, J Gryczynski, KE O’grady, JM Sharfstein, G Warren, Y Olsen, ... American journal of public health 103 (5), 917-922, 2013 | 371 | 2013 |
Opioid prescriptions by US primary care physicians from 1992 to 2001 Y Olsen, GL Daumit, DE Ford The Journal of Pain 7 (4), 225-235, 2006 | 291 | 2006 |
The association of self-reported neighborhood disorganization and social capital with adolescent alcohol and drug use, dependence, and access to treatment EL Winstanley, DM Steinwachs, ME Ensminger, CA Latkin, ML Stitzer, ... Drug and alcohol dependence 92 (1-3), 173-182, 2008 | 269 | 2008 |
Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial GM Lucas, A Chaudhry, J Hsu, T Woodson, B Lau, Y Olsen, JC Keruly, ... Annals of internal medicine 152 (11), 704-711, 2010 | 136 | 2010 |
Leaving buprenorphine treatment: patients' reasons for cessation of care J Gryczynski, SG Mitchell, JH Jaffe, KE O’Grady, YK Olsen, RP Schwartz Journal of substance abuse treatment 46 (3), 356-361, 2014 | 120 | 2014 |
Opioid use disorder in the United States: insurance status and treatment access WC Becker, DA Fiellin, JO Merrill, B Schulman, R Finkelstein, Y Olsen, ... Drug and alcohol dependence 94 (1-3), 207-213, 2008 | 117 | 2008 |
Patient perspectives on choosing buprenorphine over methadone in an urban, equal‐access system J Gryczynski, JH Jaffe, RP Schwartz, KA Dušek, N Gugsa, CL Monroe, ... The American journal on addictions 22 (3), 285-291, 2013 | 97 | 2013 |
The CDC guideline on opioid prescribing: rising to the challenge Y Olsen Jama 315 (15), 1577-1579, 2016 | 84 | 2016 |
Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use SG Mitchell, J Gryczynski, RP Schwartz, CP Myers, KE O’Grady, YK Olsen, ... Journal of psychoactive drugs 47 (2), 149-157, 2015 | 81 | 2015 |
EMS runs for suspected opioid overdose: implications for surveillance and prevention A Knowlton, BW Weir, F Hazzard, Y Olsen, J McWilliams, J Fields, ... Prehospital emergency care 17 (3), 317-329, 2013 | 79 | 2013 |
Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore O Falade-Nwulia, R Irvin, A Merkow, M Sulkowski, A Niculescu, Y Olsen, ... Journal of substance abuse treatment 100, 45-51, 2019 | 71 | 2019 |
Patient‐centered methadone treatment: a randomized clinical trial RP Schwartz, SM Kelly, SG Mitchell, J Gryczynski, KE O'Grady, D Gandhi, ... Addiction 112 (3), 454-464, 2017 | 62 | 2017 |
Retention in methadone and buprenorphine treatment among African Americans J Gryczynski, SG Mitchell, JH Jaffe, SM Kelly, CP Myers, KE O'Grady, ... Journal of substance abuse treatment 45 (3), 287-292, 2013 | 60 | 2013 |
A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans SG Mitchell, J Gryczynski, RP Schwartz, KE O’Grady, YK Olsen, JH Jaffe Drug and alcohol dependence 128 (3), 222-229, 2013 | 56 | 2013 |
Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention LB Monico, SG Mitchell, J Gryczynski, RP Schwartz, KE O’Grady, ... Journal of Substance Abuse Treatment 57, 57-62, 2015 | 49 | 2015 |
Chronic pain, addiction, and Zohydro Y Olsen, JM Sharfstein New England Journal of Medicine 370 (22), 2061-2063, 2014 | 37 | 2014 |
What is addiction? History, terminology, and core concepts Y Olsen Medical Clinics 106 (1), 1-12, 2022 | 35 | 2022 |
Chronic pain and narcotics: a dilemma for primary care Y Olsen, GL Daumit Journal of general internal medicine 17 (3), 238, 2002 | 33 | 2002 |
Overcoming barriers to treatment of opioid use disorder Y Olsen, RM Fitzgerald, SE Wakeman JAMA 325 (12), 1149-1150, 2021 | 32 | 2021 |